PBYI - プ―マ・バイオテクノロジ― (Puma Biotechnology Inc) プ―マ・バイオテクノロジ―

 PBYIのチャート


 PBYIの企業情報

symbol PBYI
会社名 Puma Biotechnology Inc. (プ―マ・バイオテクノロジ―)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 プーマ・バイオテクノロジー(Puma Biotechnology Inc.)は癌の治療用製品の開発・商品化に焦点を当てたバイオ医薬品会社である。同社は、PB272(ネラチニブ(経口))、PB272(ネラチニブ(静脈内))およびPB357を含む3つ以上の候補者に対する開発・商業化の権利をライセンス供与する。ネラチニブは、表皮成長因子受容体(EGFR)、HER1、HER2およびHER4を介したシグナル伝達をブロックする強力な不可逆的チロシンキナーゼ阻害剤(TKI)である。最初の焦点は、HER2陽性転移性乳癌患者の経口治療としてのネラチニブの開発にある。同社は、静脈内投与された薬剤としてのネラチニブの開発に焦点を当てている。ネラチニブの静脈内投与は、前臨床モデルにおけるネラチニブの暴露レベルをもたらす。製品候補であるPB357は、表皮成長因子受容体を介したシグナル伝達をブロックする不可逆的TKIである経口投与剤である。   プ―マ・バイオテクノロジ―は、開発段階のバイオ医薬品を手掛ける米国の会社。抗癌剤の開発に従事する。初期臨床試験を完了した薬やライセンス取得中の薬剤候補を中心に開発を行う。ライセンス取得済み薬剤候補は、進行乳癌患者・非小細胞肺癌患者向けPB272(経口)、進行癌患者向けPB272(静脈)、PB272のバックアップとしてPB357がある。   
本社所在地 10880 Wilshire Boulevard Suite 2150 Los Angeles CA 90024 USA
代表者氏名 Alan H. Auerbach Alan H. Auerbach
代表者役職名 Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者(CEO)
電話番号 +1 424-248-6500
設立年月日 39173
市場名 NYSE(ニューヨーク証券取引所)
ipoyear ―年
従業員数 156人
url www.pumabiotechnology.com
nasdaq_url https://www.nasdaq.com/symbol/pbyi
adr_tso
EBITDA EBITDA(百万ドル) -200.36000
終値(lastsale) 45.34
時価総額(marketcap) 1724052683.88
時価総額 時価総額(百万ドル) 1603.894
売上高 売上高(百万ドル) 144.96800
企業価値(EV) 企業価値(EV)(百万ドル) 1589.651
当期純利益 当期純利益(百万ドル) -209.93800
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Puma Biotechnology Inc revenues increased from $0K to $117.3M. Net loss decreased 54% to $68.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Basic Earnings per Share excluding Extraordinary Items increased from -$4.08 to -$1.82.

 PBYIのテクニカル分析


 PBYIのニュース

   Celcuity Announces Breast Cancer Clinical Trial Collaboration with MD Anderson, Novartis, and Puma Biotechnology to Study New Drug Regimen  2021/03/16 20:00:00 Business Wire
Celcuity Announces Breast Cancer Clinical Trial Collaboration with MD Anderson, Novartis, and Puma Biotechnology to Study New Drug Regimen
   Puma Biotechnology to Present at the Barclays Global Healthcare Conference  2021/03/04 21:15:00 Business Wire
LOS ANGELES--(BUSINESS WIRE)--Alan Auerbach, CEO & President, will present an overview of Puma Biotechnology at the virtual Barclays Global Healthcare Conference on March 11, 2021.
   Puma Biotechnology to Present at the H.C. Wainwright Global Life Sciences Conference  2021/03/02 21:20:00 Business Wire
LOS ANGELES--(BUSINESS WIRE)--Alan Auerbach will present an overview of Puma Biotechnology at H.C. Wainwright's Global Health Care Conf, available online beginning March 9, 2021.
   Samenvatting: Puma Biotechnology en Pierre Fabre passen de NERLYNX®-licentieovereenkomst aan om ook Groot-China op te nemen  2021/02/26 19:47:00 Business Wire
LOS ANGELES & CASTRES, Frankrijk--(BUSINESS WIRE)--Puma Biotechnology, Inc. (Nasdaq: PBYI), een biofarmaceutisch bedrijf, en Pierre Fabre, een toonaangevend Frans farmaceutisch bedrijf, zijn overeengekomen de voorwaarden van de licentieovereenkomst van 2019 te verlengen. Pierre Fabre exclusieve rechten om NERLYNX® (neratinib) te ontwikkelen en te commercialiseren binnen Europa, Turkije, het Midden-Oosten en Afrika. De gewijzigde overeenkomst breidt de commerciële rechten van Pierre Fabre voor N
   The Daily Biotech Pulse: Adcom Test Awaits J&J's COVID-19 Vaccine, Lilly To Supply Additional Antibody Therapy Doses To US, Regulatory Setback For Tricida  2021/02/26 13:16:52 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 25) Apyx Medical Corp (NASDAQ: APYX ) Aslan Pharmaceuticals Ltd (NASDAQ: ASLN ) (announced an $18-million private placement) Bioatla Inc (NASDAQ: BCAB ) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) Five Prime Therapeutics Inc (NASDAQ: FPRX ) Glaukos Corp (NYSE: GKOS ) Myriad Genetics, Inc. (NASDAQ: MYGN ) Organogenesis Holdings Inc (NASDAQ: ORGO ) Pacira Biosciences Inc (NASDAQ: PCRX ) (announced fourth-quarter results) Pandion Therapeutics Inc (NASDAQ: PAND ) - announced a deal to be bought by Merck & Co., Inc. (NYSE: MRK ) for $1.85 billion Pliant Therapeutics Inc (NASDAQ: PLRX ) Vanda Pharmaceuticals Inc. (NASDAQ: VNDA ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Feb. 25) Acutus Medical Inc (NASDAQ: AFIB ) Aptose Biosciences Inc (NASDAQ: APTO ) Bioventus Class A Ord Shs (Proposed) (NASDAQ: BVS ) Epizyme Inc (NASDAQ: EPZM ) Intercept Pharmaceuticals Inc (NASDAQ: ICPT ) (reacted to fourth-quarter results) Lucira Health Inc (NASDAQ: LHDX ) Opthea Spon American Depositary Receipts Representing 8 Ord Shs (NASDAQ: OPT ) Sensei Biotherapeutics Inc (NASDAQ: SNSE ) Virios Therapeutics LLC (NASDAQ: VIR ) Voyager Therapeutics Inc (NASDAQ: VYGR ) Stocks In Focus Tricida Receives Appeals Denied Letter From FDA Regarding Veverimer Tricida Inc (NASDAQ: TCDA ) said it has received an appeal denied letter, or ADL, from the FDA's Office of New Drugs in response to a formal dispute resolution request submitted in December regarding its NDA for veverimer, which is being evaluated as a treatment option for metabolic acidosis in chronic kidney disease patients.
   Celcuity Announces Breast Cancer Clinical Trial Collaboration with MD Anderson, Novartis, and Puma Biotechnology to Study New Drug Regimen  2021/03/16 20:00:00 Business Wire
Celcuity Announces Breast Cancer Clinical Trial Collaboration with MD Anderson, Novartis, and Puma Biotechnology to Study New Drug Regimen
   Puma Biotechnology to Present at the Barclays Global Healthcare Conference  2021/03/04 21:15:00 Business Wire
LOS ANGELES--(BUSINESS WIRE)--Alan Auerbach, CEO & President, will present an overview of Puma Biotechnology at the virtual Barclays Global Healthcare Conference on March 11, 2021.
   Puma Biotechnology to Present at the H.C. Wainwright Global Life Sciences Conference  2021/03/02 21:20:00 Business Wire
LOS ANGELES--(BUSINESS WIRE)--Alan Auerbach will present an overview of Puma Biotechnology at H.C. Wainwright's Global Health Care Conf, available online beginning March 9, 2021.
   Samenvatting: Puma Biotechnology en Pierre Fabre passen de NERLYNX®-licentieovereenkomst aan om ook Groot-China op te nemen  2021/02/26 19:47:00 Business Wire
LOS ANGELES & CASTRES, Frankrijk--(BUSINESS WIRE)--Puma Biotechnology, Inc. (Nasdaq: PBYI), een biofarmaceutisch bedrijf, en Pierre Fabre, een toonaangevend Frans farmaceutisch bedrijf, zijn overeengekomen de voorwaarden van de licentieovereenkomst van 2019 te verlengen. Pierre Fabre exclusieve rechten om NERLYNX® (neratinib) te ontwikkelen en te commercialiseren binnen Europa, Turkije, het Midden-Oosten en Afrika. De gewijzigde overeenkomst breidt de commerciële rechten van Pierre Fabre voor N
   The Daily Biotech Pulse: Adcom Test Awaits J&J's COVID-19 Vaccine, Lilly To Supply Additional Antibody Therapy Doses To US, Regulatory Setback For Tricida  2021/02/26 13:16:52 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 25) Apyx Medical Corp (NASDAQ: APYX ) Aslan Pharmaceuticals Ltd (NASDAQ: ASLN ) (announced an $18-million private placement) Bioatla Inc (NASDAQ: BCAB ) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) Five Prime Therapeutics Inc (NASDAQ: FPRX ) Glaukos Corp (NYSE: GKOS ) Myriad Genetics, Inc. (NASDAQ: MYGN ) Organogenesis Holdings Inc (NASDAQ: ORGO ) Pacira Biosciences Inc (NASDAQ: PCRX ) (announced fourth-quarter results) Pandion Therapeutics Inc (NASDAQ: PAND ) - announced a deal to be bought by Merck & Co., Inc. (NYSE: MRK ) for $1.85 billion Pliant Therapeutics Inc (NASDAQ: PLRX ) Vanda Pharmaceuticals Inc. (NASDAQ: VNDA ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Feb. 25) Acutus Medical Inc (NASDAQ: AFIB ) Aptose Biosciences Inc (NASDAQ: APTO ) Bioventus Class A Ord Shs (Proposed) (NASDAQ: BVS ) Epizyme Inc (NASDAQ: EPZM ) Intercept Pharmaceuticals Inc (NASDAQ: ICPT ) (reacted to fourth-quarter results) Lucira Health Inc (NASDAQ: LHDX ) Opthea Spon American Depositary Receipts Representing 8 Ord Shs (NASDAQ: OPT ) Sensei Biotherapeutics Inc (NASDAQ: SNSE ) Virios Therapeutics LLC (NASDAQ: VIR ) Voyager Therapeutics Inc (NASDAQ: VYGR ) Stocks In Focus Tricida Receives Appeals Denied Letter From FDA Regarding Veverimer Tricida Inc (NASDAQ: TCDA ) said it has received an appeal denied letter, or ADL, from the FDA's Office of New Drugs in response to a formal dispute resolution request submitted in December regarding its NDA for veverimer, which is being evaluated as a treatment option for metabolic acidosis in chronic kidney disease patients.
   Celcuity Announces Breast Cancer Clinical Trial Collaboration with MD Anderson, Novartis, and Puma Biotechnology to Study New Drug Regimen  2021/03/16 20:00:00 Business Wire
Celcuity Announces Breast Cancer Clinical Trial Collaboration with MD Anderson, Novartis, and Puma Biotechnology to Study New Drug Regimen
   Puma Biotechnology to Present at the Barclays Global Healthcare Conference  2021/03/04 21:15:00 Business Wire
LOS ANGELES--(BUSINESS WIRE)--Alan Auerbach, CEO & President, will present an overview of Puma Biotechnology at the virtual Barclays Global Healthcare Conference on March 11, 2021.
   Puma Biotechnology to Present at the H.C. Wainwright Global Life Sciences Conference  2021/03/02 21:20:00 Business Wire
LOS ANGELES--(BUSINESS WIRE)--Alan Auerbach will present an overview of Puma Biotechnology at H.C. Wainwright's Global Health Care Conf, available online beginning March 9, 2021.
   Samenvatting: Puma Biotechnology en Pierre Fabre passen de NERLYNX®-licentieovereenkomst aan om ook Groot-China op te nemen  2021/02/26 19:47:00 Business Wire
LOS ANGELES & CASTRES, Frankrijk--(BUSINESS WIRE)--Puma Biotechnology, Inc. (Nasdaq: PBYI), een biofarmaceutisch bedrijf, en Pierre Fabre, een toonaangevend Frans farmaceutisch bedrijf, zijn overeengekomen de voorwaarden van de licentieovereenkomst van 2019 te verlengen. Pierre Fabre exclusieve rechten om NERLYNX® (neratinib) te ontwikkelen en te commercialiseren binnen Europa, Turkije, het Midden-Oosten en Afrika. De gewijzigde overeenkomst breidt de commerciële rechten van Pierre Fabre voor N
   The Daily Biotech Pulse: Adcom Test Awaits J&J's COVID-19 Vaccine, Lilly To Supply Additional Antibody Therapy Doses To US, Regulatory Setback For Tricida  2021/02/26 13:16:52 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 25) Apyx Medical Corp (NASDAQ: APYX ) Aslan Pharmaceuticals Ltd (NASDAQ: ASLN ) (announced an $18-million private placement) Bioatla Inc (NASDAQ: BCAB ) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) Five Prime Therapeutics Inc (NASDAQ: FPRX ) Glaukos Corp (NYSE: GKOS ) Myriad Genetics, Inc. (NASDAQ: MYGN ) Organogenesis Holdings Inc (NASDAQ: ORGO ) Pacira Biosciences Inc (NASDAQ: PCRX ) (announced fourth-quarter results) Pandion Therapeutics Inc (NASDAQ: PAND ) - announced a deal to be bought by Merck & Co., Inc. (NYSE: MRK ) for $1.85 billion Pliant Therapeutics Inc (NASDAQ: PLRX ) Vanda Pharmaceuticals Inc. (NASDAQ: VNDA ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Feb. 25) Acutus Medical Inc (NASDAQ: AFIB ) Aptose Biosciences Inc (NASDAQ: APTO ) Bioventus Class A Ord Shs (Proposed) (NASDAQ: BVS ) Epizyme Inc (NASDAQ: EPZM ) Intercept Pharmaceuticals Inc (NASDAQ: ICPT ) (reacted to fourth-quarter results) Lucira Health Inc (NASDAQ: LHDX ) Opthea Spon American Depositary Receipts Representing 8 Ord Shs (NASDAQ: OPT ) Sensei Biotherapeutics Inc (NASDAQ: SNSE ) Virios Therapeutics LLC (NASDAQ: VIR ) Voyager Therapeutics Inc (NASDAQ: VYGR ) Stocks In Focus Tricida Receives Appeals Denied Letter From FDA Regarding Veverimer Tricida Inc (NASDAQ: TCDA ) said it has received an appeal denied letter, or ADL, from the FDA's Office of New Drugs in response to a formal dispute resolution request submitted in December regarding its NDA for veverimer, which is being evaluated as a treatment option for metabolic acidosis in chronic kidney disease patients.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 プ―マ・バイオテクノロジ― PBYI Puma Biotechnology Inc)

 twitter  (公式ツイッターやCEOツイッターなど)